Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1
Status:
Completed
Trial end date:
1997-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone
sublingual tablet formulation as an office-based therapy for opiate-dependence treatment. The
developmental objective for this combination product is an expansion of therapeutic options
for the treatment of opiate dependence.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborator:
Cincinnati MDRU
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Naloxone